Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Zacks Investment Research on MSN23h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback